Top stories of 2022 for cancer cell and gene therapy.

2022 has been a year filled with triumphs for the field of cancer cell and gene therapy. Breakthroughs in research, survivor milestones, FDA approvals and more have defined a great year for this emerging field of cancer treatment.

Alliance for Cancer Gene Therapy’s staff compiled a list of the top stories in 2022 for cancer cell and gene therapy. Let’s reflect on the recent accomplishments as we embark on a new year with new goals in the hope of continuing to transform cancer treatment.

ACGT scientist Brian Brown, PhD, making progress with macrophage therapy.

Brian Brown, PhD, an ACGT Research Fellow, is making progress in his ACGT-funded development of a CAR T-cell therapy to target a particular immune cell called macrophages. In tests on mice subjects, Dr. Brown’s new therapy shrank tumors by killing macrophages and causing a positive immune response.

Dr. Brown, who works at Icahn School of Medicine at Mount Sinai, reported that killing tumor-aligned macrophage cells makes many types of solid tumors including ovarian, lung and pancreatic cancer more vulnerable to the immune system. This recent progress is the result of ACGT’s dedication to funding revolutionary cancer research projects and our donors’ belief in ACGT’s mission.

Donate to ACGT before the year ends.

As the end of 2022 approaches, everyone at Alliance for Cancer Gene Therapy wishes you and your family a happy holidays. These last few weeks are a final opportunity to make an impact in the fight against cancer by supporting cell and gene therapy science.

Please consider donating before the end of the year. With one final surge in fundraising, 2022 will be one of the best years yet in our effort to advance cell and gene therapy research.

In the news

The latest from around the cancer cell and gene therapy research world.

Barbara Lavery, Chief Program Officer of ACGT, will be participating in the 9th-annual Immuno-Oncology 360° Summit taking place February 7-10, 2023, at the New York Marriott at the Brooklyn Bridge in Brooklyn. The IO360 Summit offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting immuno-oncology.

Plenary topics include Cell Therapy, Biomarkers, Assay Development, Discovery, Preclinical, Imaging Advancements, Clinical Operations, Business Developments, Translational Science, RNA Therapeutics, and Clinical Developments.

Attendees can access a 15% discount with the code “ACGT15”. Learn more at www.IO360Summit.com